PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, November 6, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors inter ...

Core Insights - Treace Medical Concepts, Inc. is showcasing new product innovations and presenting interim data from the ALIGN3D and MTA3D clinical studies at the AOFAS Annual Meeting 2025 [1][2] Product Innovations - The company is highlighting the full commercial release of its expanded bunion portfolio, which includes new technologies such as Nanoplasty, Percuplasty, SpeedMTP, and IntelliGuide PSI, aimed at improving surgical outcomes for bunion patients [2][4] - The Nanoplasty procedure allows for 3D minimally invasive osteotomies through a single 1.5cm incision, while Percuplasty utilizes 0.5cm percutaneous incisions for a more efficient approach [4] - SpeedMTP provides a fusion option for bunion patients with arthritic great toe joints, combining advanced fixation technology for stability [4] - IntelliGuide PSI offers personalized 3D-printed cut guides for enhanced surgical workflow [4] Clinical Study Presentations - The ALIGN3D clinical study presented interim data showing early return to weight bearing in an average of 8.4 days and low radiographic recurrence rates of 7.7% at 48 months and 4.8% at 60 months [5][6] - The MTA3D clinical study is assessing outcomes following combined Adductoplasty and Lapiplasty procedures, with interim data showing significant improvements in pain and patient-reported scores at 12 months [7][12] Company Overview - Treace Medical Concepts aims to advance the standard of care for surgical management of bunions and related midfoot deformities, addressing a market of approximately 65 million Americans, with an estimated 1.1 million surgical candidates annually [11] - The company has developed the Lapiplasty 3D Bunion Correction System, which corrects bunion deformities in all three planes and secures the unstable joint [11][13]